Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

Phase 1 Completed 60 enrolled Dong-A ST Co., Ltd.

RandomizedCrossoverOpen-labelTreatment

Summary

This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and Forxiga® after a single oral dose in healthy volunteers. The study will also compare the pharmacokinetics and safety profiles of DA-2811 under fasting and fed states in healthy subjects.

Timeline

Start: 2020-08-04
Primary completion: 2020-08-26
Completion: 2020-10-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DA-2811	Unknown	—	Oral
Subject	Forxiga	Unknown	—	Oral

Indications

No indication recorded.